Cooper Jeffrey H Form 4 May 16, 2012

## FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB APPROVAL** 

**OMB** 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per response... 0.5

if no longer subject to Section 16. Form 4 or Form 5

obligations

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

1. Name and Address of Reporting Person \* Cooper Jeffrey H

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

**BIOMARIN PHARMACEUTICAL** INC [BMRN]

(Check all applicable)

(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)

Director 10% Owner \_X\_\_ Officer (give title Other (specify

04/30/2012

below) SVP, Chief Financial Officer

C/O BIOMARIN PHARMACEUTICAL INC., 10 **DIGITAL DRIVE** 

> 4. If Amendment, Date Original (Street)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

**NOVATO, CA 94949** 

(City)	(State)	(Zip) Tab	le I - Non-l	Derivative	Secur	ities Acquir	ed, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	onor Dispose (Instr. 3, 4	ed of (4 and 5 (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/30/2012(1)	04/30/2012	Code V A V	Amount 985	(D)	Price \$ 19.346	,	D	
Common Stock	05/14/2012(2)	05/14/2012	M	15,000	A	\$ 26.49	56,089	D	
Common Stock	05/14/2012(2)	05/14/2012	M	6,500	A	\$ 21.51	62,589	D	
Common Stock	05/14/2012(2)	05/14/2012	M	3,750	A	\$ 14.39	66,339	D	
	05/14/2012(2)	05/14/2012	S	25,250	D		41,089	D	

### Edgar Filing: Cooper Jeffrey H - Form 4

Common	\$
Stock	38.0878
	(3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisal Expiration Date (Month/Day/Year		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (right to buy)	\$ 26.49	05/14/2012(2)	05/14/2012	M	15,000	11/12/2011 <u>(4)</u>	05/11/2021	Common Stock	15,000
Stock Option (right to buy)	\$ 21.51	05/14/2012(2)	05/14/2012	M	6,500	11/12/2010(5)	05/11/2020	Common Stock	6,500
Stock Option (right to buy)	\$ 14.39	05/14/2012(2)	05/14/2012	M	3,750	11/12/2009(6)	05/11/2019	Common Stock	3,750

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Cooper Jeffrey H						
C/O BIOMARIN PHARMACEUTICAL INC.			SVD Chief Eineneiel Officer			

10 DIGITAL DRIVE **NOVATO, CA 94949**  SVP, Chief Financial Officer

Reporting Owners 2

## **Signatures**

/s/ Laura Randall Woodhead, Attorney-in-Fact

05/16/2012

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's Employee Stock Purchase Plan ("ESPP"), for the ESPP period of November 1,2011 to April 30, 2012.
- (2) Transaction made pursuant to a Rule 10b5-1 Trading plan executed March 6, 2012.
  - The price in Column 4 is a weighted average price. The prices actually received ranged from \$37.31 to \$38.6325. The reporting person
- (3) will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (4) Original option grant vested 6/48ths on November 12, 2011 and 1/48th on the 12th of every month thereafter.
- (5) Original option grant vested 6/48ths on November 12, 2010 and 1/48th on the 12th of every month thereafter.
- (6) Original option grant vested 6/48ths on November 12, 2009 and 1/48th on the 12th of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3